We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BioScrip's Deal with Home Solutions Revised, To Close Soon
Read MoreHide Full Article
While further amending the terms of its earlier announced agreement to acquire the Home Solutions business, BioScrip, Inc. recently noted that the transaction is expected to close by the second week of September.
We note that in its effort to fully concentrate on the Infusion Services business, earlier in June, the company agreed to acquire HS Infusion Holdings, Inc.’s home infusion and home nursing products and services business, Home Solutions.
Home Solutions particularly caters to patients suffering from chronic and acute medical conditions. While the initial closing consideration was $85 million, it was reduced to $75 million later on. The cash component of the consideration was reduced from $80.0 million to $67.5 million.
The latest amendment of the Asset Purchase Agreement specifies that in order to facilitate the timely closure of this transaction, BioScrip and Home Solutions will eliminate the need for stockholders’ approval required to increase its authorized share capital. Instead, they have agreed to a shareholder meeting after transaction closure to seek such approval and provide Home Solutions with certain contractual protections in the event such approval is not obtained.
The combined company is expected to generate revenues of more than $1 billion. Additionally, the acquisition, while accelerating the company’s growth in core business, is likely to generate substantial synergies of between $14−$17 million in cost savings within approximately 12−18 months following the completion. In terms of operating synergy, the inclusion of Home Solutions will benefit BioScrip with respect to supply chain efficiencies, infrastructure optimization, and other corporate and organizational improvements.
We note that over the recent past, BioScrip has been recording persistent growth in its core Infusion Services business where it has a strong presence and enjoys a competitive advantage. BioScrip has already taken a number of steps to focus on the core Infusion business in order to drive further growth therein.
These include the sale of its legacy specialty and mail service pharmacies; the sale of its home health services business; the latest divestment of the PBM business to ProCare Rx; and its plan to sell or transition 9 core patient service activities accumulated through acquisitions, to alliance pharmacy providers.
The company has been engaged in a handful of takeovers and sellouts in recent times as well, the latest example being the impending buyout of Home Solutions. Currently, BioScrip continues to evaluate a huge pipeline of acquisition opportunities to further expand its infusion footprint in the U.S.
Currently, BioScrip carries a Zacks Rank #3 (Hold).
Key Picks in the Sector
Some better-ranked stocks in the broader medical space are Almost Family Inc. , RadNet, Inc. (RDNT - Free Report) and US Physical Therapy Inc. (USPH - Free Report) . All the three stocks carry a Zacks Rank #2 (Buy).
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
BioScrip's Deal with Home Solutions Revised, To Close Soon
While further amending the terms of its earlier announced agreement to acquire the Home Solutions business, BioScrip, Inc. recently noted that the transaction is expected to close by the second week of September.
We note that in its effort to fully concentrate on the Infusion Services business, earlier in June, the company agreed to acquire HS Infusion Holdings, Inc.’s home infusion and home nursing products and services business, Home Solutions.
Home Solutions particularly caters to patients suffering from chronic and acute medical conditions. While the initial closing consideration was $85 million, it was reduced to $75 million later on. The cash component of the consideration was reduced from $80.0 million to $67.5 million.
The latest amendment of the Asset Purchase Agreement specifies that in order to facilitate the timely closure of this transaction, BioScrip and Home Solutions will eliminate the need for stockholders’ approval required to increase its authorized share capital. Instead, they have agreed to a shareholder meeting after transaction closure to seek such approval and provide Home Solutions with certain contractual protections in the event such approval is not obtained.
The combined company is expected to generate revenues of more than $1 billion. Additionally, the acquisition, while accelerating the company’s growth in core business, is likely to generate substantial synergies of between $14−$17 million in cost savings within approximately 12−18 months following the completion. In terms of operating synergy, the inclusion of Home Solutions will benefit BioScrip with respect to supply chain efficiencies, infrastructure optimization, and other corporate and organizational improvements.
We note that over the recent past, BioScrip has been recording persistent growth in its core Infusion Services business where it has a strong presence and enjoys a competitive advantage. BioScrip has already taken a number of steps to focus on the core Infusion business in order to drive further growth therein.
These include the sale of its legacy specialty and mail service pharmacies; the sale of its home health services business; the latest divestment of the PBM business to ProCare Rx; and its plan to sell or transition 9 core patient service activities accumulated through acquisitions, to alliance pharmacy providers.
The company has been engaged in a handful of takeovers and sellouts in recent times as well, the latest example being the impending buyout of Home Solutions. Currently, BioScrip continues to evaluate a huge pipeline of acquisition opportunities to further expand its infusion footprint in the U.S.
Currently, BioScrip carries a Zacks Rank #3 (Hold).
Key Picks in the Sector
Some better-ranked stocks in the broader medical space are Almost Family Inc. , RadNet, Inc. (RDNT - Free Report) and US Physical Therapy Inc. (USPH - Free Report) . All the three stocks carry a Zacks Rank #2 (Buy).
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>